Fridberg, G.; Amit, O.; Karni, C.; Tshernichovsky, D.; Shasha, D.; Rouach, V.; Varssano, D.; Bar-Shai, A.; Goldberg, I.; Wasserman, G.;
et al. The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes—A Single-Center Longitudinal Cohort Analysis. Cancers 2024, 16, 3521.
https://doi.org/10.3390/cancers16203521
AMA Style
Fridberg G, Amit O, Karni C, Tshernichovsky D, Shasha D, Rouach V, Varssano D, Bar-Shai A, Goldberg I, Wasserman G,
et al. The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes—A Single-Center Longitudinal Cohort Analysis. Cancers. 2024; 16(20):3521.
https://doi.org/10.3390/cancers16203521
Chicago/Turabian Style
Fridberg, Gil, Odelia Amit, Chen Karni, Dina Tshernichovsky, David Shasha, Vanessa Rouach, David Varssano, Amir Bar-Shai, Ilan Goldberg, Gilad Wasserman,
and et al. 2024. "The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes—A Single-Center Longitudinal Cohort Analysis" Cancers 16, no. 20: 3521.
https://doi.org/10.3390/cancers16203521
APA Style
Fridberg, G., Amit, O., Karni, C., Tshernichovsky, D., Shasha, D., Rouach, V., Varssano, D., Bar-Shai, A., Goldberg, I., Wasserman, G., Avivi, I., & Ram, R.
(2024). The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes—A Single-Center Longitudinal Cohort Analysis. Cancers, 16(20), 3521.
https://doi.org/10.3390/cancers16203521
